Both Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of
systemic and neuro-inflammation, enhanced production and accumulation of β-amyloid …

Plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-
α), and lipid peroxides are elevated and concentrations of endothelial nitric oxide (eNO) …

Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …

Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase
(BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly,
characterised by widespread loss central cholinergic function. The only symptomatic …

Cholinesterase inhibitors are the standard of care for Alzheimer's disease (AD).
Acetylcholinesterase (AChE) catalyzes the hydrolysis of the cholinergic neurotransmitter …

The brain of mammals contains two major forms of cholinesterases (ChEs):
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The two forms differ …

Alzheimer's disease and type 2 diabetes mellitus tend to occur together. We sought to
identify protein (s) common to both conditions that could suggest a possible unifying …

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by
cognitive decline associated with a deficit in cholinergic function. Inhibitors of …